Pseudomonas aeruginosa peptidoglycan (PGN)

Pseudomonas aeruginosa peptidoglycan is a vital structural heteropolymer located in the periplasmic space of this Gram-negative bacterium, providing the mechanical strength necessary to withstand osmotic pressure and maintain cell shape (Vollmer et al., 2008). It consists of a glycan backbone of alternating N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) residues, which are cross-linked by short peptide chains to form a robust, mesh-like network known as murein (Silhavy et al., 2010). In the context of P. aeruginosa infections, which are particularly prevalent in immunocompromised patients and those with cystic fibrosis, this structure is the primary target for several major classes of antibiotics, including beta-lactams, carbapenems, and monobactams (Breidenstein et al., 2011). These drugs function by inhibiting penicillin-binding proteins (PBPs), the enzymes responsible for the final stages of peptidoglycan assembly and cross-linking, leading to cell wall instability and osmotic lysis (Pazos & Vollmer, 2021). Beyond its structural role, peptidoglycan fragments released during bacterial growth or antibiotic-induced lysis act as potent pathogen-associated molecular patterns (PAMPs) that trigger the host's innate immune system via intracellular receptors like NOD1 and NOD2 (Irazoki et al., 2019). Consequently, the metabolism and integrity of P. aeruginosa peptidoglycan are central to both the pathogen's survival and the host's inflammatory response during infection.

Other names

MureinBacterial cell wall peptidoglycanP. aeruginosa cell wallPeptidoglycan layer

Inhibition of peptidoglycan biosynthesis by binding to and inactivating penicillin-binding proteins (PBPs), which prevents the cross-linking of peptidoglycan strands, or by inhibiting early cytoplasmic stages of precursor synthesis.